1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France

Background

HER2 targeted treatment impacted the management of NSCLC patients (pts) with HER2 mutations; however, real-world data on HER2 testing in NSCLC pts is limited. This abstract aims to describe HER2 testing and characteristics of locally advanced or metastatic (LAM) NSCLC pts in France.

Methods

This is a retrospective analysis of observational data from the EpidemioStrategy and Medical Economics (ESME) Lung Cancer Database from France (NCT03848052). Patients >18 years diagnosed with LAM NSCLC from 2015 without any other previous malignancy were included in the analysis.

Results

ESME includes 22561 LAM NSCLC pts who met the eligibility criteria. Of those, 33.4% received at least 1 HER2 test and 10.3% of tested pts received >1 test. HER2 testing decreased over time (2015 27.7%, 2016 21.0%, 2017 17.1%, 2018 12.6%, 2019 9.7%, 2020 3.7%). 2.5% of tested pts had HER2 alteration. 81.4% of LAM NSCLC pts received HER2 testing after LAM NSCLC diagnosis, with a median time of 28 days from LAM NSCLC diagnosis to test result. 58.2% received first HER2 test result before 1st line treatment, and the median time to treatment start from the test result was 20 days. Primary tumor tissue was the most common sample material for HER2 testing (71.5% of pts), followed by metastasis tissue (27.4%) and blood (3.9%). Age at initial and LAM-NSCLC diagnosis were similar between HER2 tested and not tested pts. However, the HER2 tested group had a higher proportion of female pts and those ≤60 years old. Pts with ECOG PS record showed that HER2-tested pts had better performance status. HER2 tested group had higher proportion of non-squamous NSCLC (95.3% vs 69.7%) and more pts were diagnosed with de novo LAM NSCLC (80.2% vs 74.0%) and at stage 4 (84.2% vs 76.8%). Table: 1396P

Characteristics of LAM NSCLC patients by HER2 test status

* based on number of pts with ECOG PS records

Conclusions

These results revealed that HER2 testing rates for LAM NSCLC pts were low and have decreased over time, with a remarkable drop in 2020 in France; and NSCLC pts with specific characteristics had higher HER2 testing rate.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Unicancer.

Funding

The ESME Lung Cancer Database receives financial support from industrial partners (AstraZeneca, Roche, Janssen, MSD, BMS, Amgen). Unicancer manages the database (i.e. data collection, analysis and publication) independently.

Disclosure

D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Pfizer, OSE Immunotherapeutics, Novartis, SanofiAventis, Amgen, Roche, Ipsen; Financial Interests, Personal, Invited Speaker: Gilead, Takeda, Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Novartis, Takeda, Bayer, SanofiAventis. P. Macouillard: Financial Interests, Institutional, Full or part-time Employment: Unicancer. M. Berktas: Financial Interests, Personal, Other, I receive regular consultancy fee for my scientific services I am the project lead for the project from which 2 abstracts were created and submitted to ESMO 2023 congress: AstraZeneca. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. C. Audigier Valette: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, AstraZeneca, Sanofi, Janssen; Financial Interests, Personal, Invited Speaker: Pfizer. T. Filleron: Financial Interests, Personal, Other, working group: Janssen-Cilag,; Financial Interests, Institutional, Invited Speaker: Lilly; Financial Interests, Institutional, Other, working group: Roche; Other, Consulting (compensated to my institution): Cellectis. S. Musilli: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca. L. Bosquet: Financial Interests, Institutional, Full or part-time Employment, In charge of scientific projects at Unicancer, Health Data and Partnership Department: Unicancer. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Other, DMSB: Roche. All other authors have declared no conflicts of interest.